β-synuclein in cerebrospinal fluid as a potential biomarker for distinguishing human prion diseases from Alzheimer’s and Parkinson’s disease
Abstract Background β-synuclein (β-syn), mainly expressed in central nerve system, is one of the biomarkers in cerebrospinal fluid (CSF) and blood for synaptic damage, which has been reported to be elevated in CSF and blood of the patients of prion diseases (PrDs). Methods We analyzed 314 CSF sample...
Saved in:
Main Authors: | Bing Xu, Kang Xiao, Xiaoxi Jia, Rundong Cao, Donglin Liang, Ruhan A, Weiwei Zhang, Chunjie Li, Liping Gao, Cao Chen, Qi Shi, Xiaoping Dong |
---|---|
Format: | Article |
Language: | English |
Published: |
BMC
2025-02-01
|
Series: | Alzheimer’s Research & Therapy |
Subjects: | |
Online Access: | https://doi.org/10.1186/s13195-025-01688-9 |
Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Similar Items
-
Neurofilament Light Chain Levels in Serum and Cerebrospinal Fluid Do Not Correlate with Survival Times in Patients with Prion Disease
by: Mika Shimamura, et al.
Published: (2024-12-01) -
Unmet needs of biochemical biomarkers for human prion diseases
by: Peter Hermann, et al.
Published: (2024-12-01) -
Emerging targets of α-synuclein spreading in α-synucleinopathies: a review of mechanistic pathways and interventions
by: Grace Kuo, et al.
Published: (2025-01-01) -
Refining α-synuclein seed amplification assays to distinguish Parkinson’s disease from multiple system atrophy
by: James A. Wiseman, et al.
Published: (2025-02-01) -
Recursive seed amplification detects distinct α-synuclein strains in cerebrospinal fluid of patients with Parkinson’s disease
by: Stefan Bräuer, et al.
Published: (2025-01-01)